- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00811941
Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence (SENSE)
July 5, 2013 updated by: H. Lundbeck A/S
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence
The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Alcohol dependence is a maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested by at least three of a number of criteria such as tolerance, withdrawal symptoms, frequent use of alcohol in larger amounts or over longer periods than was intended, and others.
Excessive intake of alcohol reduces the life span by a decade, and alcohol drinking is strongly related to mortality from liver cirrhosis, chronic pancreatitis, certain cancers, hypertension, accidents and violence.
This study is planned to evaluate the long-term safety and tolerability as well as to evaluate the efficacy of as needed use of 18.06 mg nalmefene in patients with alcohol dependence.
Study Type
Interventional
Enrollment (Actual)
665
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Litomerice, Czech Republic, 412 01
- CZ007
-
Lnare, Czech Republic, 38742
- CZ006
-
Prague, Czech Republic, 100 00
- CZ005
-
Praha 6, Czech Republic, 160 00
- CZ004
-
Usti nad Labem, Czech Republic, 400 13
- CZ001
-
-
-
-
-
Parnu, Estonia, 80012
- EE002
-
Tallinn, Estonia, 10613
- EE004
-
Tallinn, Estonia, 10613
- EE005
-
Voru, Estonia, 65608
- EE001
-
Vorumaa, Estonia, 65526
- EE003
-
-
-
-
-
Budapest, Hungary, 1135
- HU004
-
Budapest, Hungary, 1163
- HU002
-
-
-
-
-
Daugavpils, Latvia, 5403
- LV003
-
Jelgava, Latvia, 3008
- LV002
-
Riga, Latvia, 1013
- LV001
-
Sigulda, Latvia, 2150
- LV004
-
-
-
-
-
Kaunas, Lithuania, 44184
- LT002
-
Kaunas, Lithuania, 50185
- LT003
-
-
-
-
-
Belchatow, Poland, 97-400
- PL015
-
Bydgoszcz, Poland, 85-096
- PL008
-
Gdansk, Poland, 80-211
- PL006
-
Krakow, Poland, 31-826
- PL011
-
Leszno, Poland, 64-100
- PL002
-
Lodz, Poland, 91-229
- PL010
-
Lodz, Poland, 91-229
- PL014
-
Lublin, Poland, 20-015
- PL004
-
Lublin, Poland, 20-109
- PL005
-
Piekary Slaskie, Poland, 41-940
- PL013
-
Skorzewo, Poland, 60-185
- PL003
-
Starogard Gdanski, Poland, 83-200
- PL007
-
Swicie n/Wisla, Poland, 86-100
- PL012
-
Szczecin, Poland, 71-460
- PL009
-
Torun, Poland, 87-100
- PL001
-
-
-
-
-
Leningrad, Russian Federation, 18861
- RU002
-
Rostov on Don, Russian Federation, 344010
- RU013
-
St. Petersburg, Russian Federation, 192019
- RU006
-
St. Petersburg, Russian Federation, 192019
- RU005
-
St. Petersburg, Russian Federation, 193015
- RU001
-
St. Petersburg, Russian Federation, 194022
- RU012
-
St. Petersburg, Russian Federation, 197198
- RU003
-
Voronezh, Russian Federation, 394000
- RU004
-
-
-
-
-
Banska Bysterica, Slovakia, 974 01
- SK001
-
Krupina, Slovakia, 963 01
- SK002
-
Nitra, Slovakia, 949 01
- SK004
-
Rimavska Sobota, Slovakia, 97912
- SK005
-
-
-
-
-
Chernihiv, Ukraine, 14000
- UA001
-
Dnipropetrovsk, Ukraine, 49616
- UA008
-
Donetsk, Ukraine, 83037
- UA003
-
Glevakha, Ukraine, 8630
- UA004
-
Kharkiv, Ukraine, 61068
- UA007
-
Kherson, Ukraine, 73488
- UA009
-
Kyiv, Ukraine, 4080
- UA002
-
Odessa, Ukraine, 65006
- UA005
-
Simferopol, Ukraine, 95006
- UA006
-
Ternopil, Ukraine, 46020
- UA010
-
-
-
-
-
Birmingham, United Kingdom, B15 2SQ
- GB007
-
Glasgow, United Kingdom
- GB006
-
London, United Kingdom
- GB009
-
Manchester, United Kingdom, M15 6SX
- GB008
-
Reading, United Kingdom, RG2 0TG
- GB005
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
In- and outpatients who:
- had a primary diagnosis of alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders - text revision (DSM-IV-TR) criteria
- had had ≥6 Heavy Drinking Days (HDDs) in the 4 weeks preceding the Screening Visit
Exclusion Criteria:
The patient:
- had a severe psychiatric disorder or an antisocial personality disorder
- had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)
- had a history of delirium tremens or alcohol withdrawal seizures
- reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists
- was pregnant or breast-feeding
Other protocol-defined inclusion and exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
as-needed use, tablets, orally, 52 weeks
|
Experimental: Nalmefene
|
18.06 mg as-needed use, tablets, orally, 52 weeks.
18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients Who Withdrew Due to Intolerance to Treatment
Time Frame: Baseline to Week 52
|
Baseline to Week 52
|
|
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
Time Frame: Baseline and Month 6
|
Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 grams (g) for men and ≥40 g for women.
|
Baseline and Month 6
|
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
Time Frame: Baseline and Month 6
|
TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
|
Baseline and Month 6
|
Number of Patients With Adverse Events (AEs)
Time Frame: Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.
|
Overview of AEs
|
Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drinking Risk Level (RSDRL) Response
Time Frame: Month 6
|
RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.
|
Month 6
|
Change From Baseline in Clinical Status Using CGI-S
Time Frame: Baseline and Week 24
|
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness.
The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
|
Baseline and Week 24
|
Liver Function Test Gamma-glutamyl Transferase (GGT)
Time Frame: Week 24
|
GGT values
|
Week 24
|
Liver Function Test Alanine Aminotransferase (ALAT)
Time Frame: Week 24
|
ALAT values
|
Week 24
|
Change in Clinical Status Using the CGI-I
Time Frame: Week 24
|
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening).
The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).
|
Week 24
|
Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)
Time Frame: Baseline and Month 13
|
Number of HDDs over a month (28 days), where one HDD was defined as a day with alcohol consumption ≥60 g for men and ≥40 g for women.
|
Baseline and Month 13
|
Change From Baseline in the Monthly Total Alcohol Consumption (TAC)
Time Frame: Baseline and Month 13
|
TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
|
Baseline and Month 13
|
Drinking Risk Level (RSDRL) Response
Time Frame: Month 13
|
RSDRL response was defined as a downward shift from baseline in Drinking Risk Level (DRL); for patients at very high risk at Baseline: a shift to medium risk or below, and for patients at high or medium risk at Baseline: a shift to low risk or below.
|
Month 13
|
Change From Baseline in Clinical Status Using CGI-S
Time Frame: Baseline and Week 52
|
The Clinical Global Impression - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness.
The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
|
Baseline and Week 52
|
Change in Clinical Status Using the CGI-I
Time Frame: Week 52
|
The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening).
The clinician assesses the patient's condition relative to a baseline on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse).
|
Week 52
|
Liver Function Test Gamma-glutamyl Transferase (GGT)
Time Frame: Week 52
|
GGT values
|
Week 52
|
Liver Function Test Alanine Aminotransferase (ALAT)
Time Frame: Week 52
|
ALAT values
|
Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
November 1, 2010
Study Completion (Actual)
November 1, 2010
Study Registration Dates
First Submitted
December 18, 2008
First Submitted That Met QC Criteria
December 18, 2008
First Posted (Estimate)
December 19, 2008
Study Record Updates
Last Update Posted (Estimate)
August 7, 2013
Last Update Submitted That Met QC Criteria
July 5, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12013A
- 2007-002315-92 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Dependence
-
University Hospital, LilleCompleted
-
Tel-Aviv Sourasky Medical CenterMinistry of Health, IsraelUnknownAlcohol-dependenceIsrael
-
Pop Test Oncology LLCBaylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaboratorsCompletedPotential Treatment for Alcohol Dependence-Alcohol InteractionUnited States
-
DynamiCare HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA); RANDActive, not recruitingAlcohol Dependence | Alcohol Use Disorder | Drug DependenceUnited States
-
National Institute on Alcohol Abuse and Alcoholism...CompletedAlcohol Abuse | Alcohol Dependence (Primary Condition)United States
-
University Hospital, Gentofte, CopenhagenCompleted
-
Massachusetts General HospitalCompletedAlcohol Dependence | Drug Abuse | Alcohol Abuse | Drug DependenceUnited States
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States